Acetylon Pharmaceuticals to Present at UBS Global Healthcare Conference

May 20, 2013

BOSTON, Mass. – May 20, 2013 – Acetylon Pharmaceuticals Inc., the leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that Walter C. Ogier, President and Chief Executive Officer of Acetylon, will present at the UBS Global Healthcare Conference today, May 20, 2013, at 1:00 p.m. ET in New York City in the Riverside South room at the New York Sheraton Hotel. 

Mr. Ogier will discuss Acetylon's clinical and preclinical development programs, with a focus on its lead drug candidate ACY-1215. ACY-1215 is an oral, small molecule, selective inhibitor of histone deacetylase 6 (HDAC6) which is currently in clinical trials for the treatment of relapsed and refractory multiple myeloma at major US cancer centers, including a Phase 1b trial in combination with Revlimid® (lenalidomide, Celgene) and a Phase 1/2 trial with Velcade® (bortezomib, Takeda Millennium).

 

About ACY-1215 
Blood cancers such as multiple myeloma are characterized by successive genetic mutations resulting in rapid cell proliferation and excess production of intracellular proteins. ACY-1215 selectively inhibits the intracellular enzyme HDAC6, leading to inactivation of the "aggresome" pathway for degradation of damaged proteins. The resultant accumulation of excess waste protein in malignant cells triggers programmed cell death, called "apoptosis," with little or no effect on normal cells. Currently available HDAC drugs non-selectively target multiple HDAC enzymes including those of Class I, resulting in dysregulated expression of numerous genes in normal cells as well as cancer cells. Side effects commonly associated with non-selective epigenetic HDAC drugs include gastrointestinal dysfunction, lowered blood platelet levels and risk of hemorrhage, and profound fatigue as well as potential for severe cardiac complications. Selective inhibition of HDAC6 is expected to reduce or eliminate these often-severe side effects associated with non-selective HDAC inhibition and may enable the development of optimized treatment regimens including maximally effective combination drug therapies.

 

About Acetylon Pharmaceuticals, Inc. 
Acetylon Pharmaceuticals Inc. is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhanced therapeutic outcome of cancer and other critical unmet medical needs. The Company’s epigenetic drug discovery platform has initially yielded a proprietary library of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases, including cancer, sickle cell disease, beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon’s lead drug candidate, ACY-1215, is a selective HDAC6 inhibitor in clinical development for the treatment of multiple myeloma. www.acetylon.com

Revlimid® is a registered trademark of Celgene Corporation. Velcade® is a registered trademark of Millennium: the Takeda Oncology Company.

 

 

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.